Analysts See $-0.06 EPS for Tyme Technologies, Inc. (TYME)

January 23, 2018 - By Maria Brooks

 Analysts See $ 0.06 EPS for Tyme Technologies, Inc. (TYME)

Analysts expect Tyme Technologies, Inc. (NASDAQ:TYME) to report $-0.06 EPS on February, 13.They anticipate $0.02 EPS change or 50.00 % from last quarter’s $-0.04 EPS. After having $-0.06 EPS previously, Tyme Technologies, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 0.16% or $0.01 during the last trading session, reaching $6.08. About 179,261 shares traded or 11.85% up from the average. Tyme Technologies, Inc. (NASDAQ:TYME) has 0.00% since January 23, 2017 and is . It has underperformed by 16.70% the S&P500.

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. The company has market cap of $543.07 million. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. It currently has negative earnings.

More notable recent Tyme Technologies, Inc. (NASDAQ:TYME) news were published by: Globenewswire.com which released: “Tyme Technologies, Inc. Announces $8.2 Million Private Placement” on March 22, 2017, also Globenewswire.com with their article: “Tyme Technologies, Inc. Announces the Issuance of Two New Platform Patents” published on August 14, 2017, Globenewswire.com published: “Tyme Technologies Announces Hiring of Shabnam Stanicky as Clinical Operations …” on January 06, 2017. More interesting news about Tyme Technologies, Inc. (NASDAQ:TYME) were released by: Globenewswire.com and their article: “Tyme Technologies Inc. (Nasdaq: TYME) to Ring The Nasdaq Stock Market Opening Bell” published on August 07, 2017 as well as Globenewswire.com‘s news article titled: “Tyme Technologies Presents Positive Interim Clinical Data in Recurrent, Non …” with publication date: June 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.